首页> 外文期刊>Journal of organ dysfunction >Cell-based therapies for acute liver failure: Human tissue engineering, pure cell implantation and stem cell application
【24h】

Cell-based therapies for acute liver failure: Human tissue engineering, pure cell implantation and stem cell application

机译:急性肝衰竭的细胞疗法:人体组织工程,纯细胞植入和干细胞应用

获取原文
获取原文并翻译 | 示例
       

摘要

Improving the survival rate and quality of life of patients with acute and chronic hepatic dysfunction still represents a challenge. Cell-based therapeutic hepatocyte transplantation has great potential to serve as a temporary support and "bridge" prior to a donor organ becoming available, or even as therapy for replacing a compromised liver. In this review we describe potential applications of human tissue engineering, compare therapeutic effects of transplanted hepatocytes, with or without tissue engineering and highlight the exciting progress of stem cell transplantation in hepatic dysfunction. Hepatocytes can be transplanted in the form of pure cells or as cells engineered with devices (with or without pretreatment with growth factors), freshly isolated or preserved cells or adult matured or stem cells. The efficacy of different forms of cell-based therapy may be associated with the severity and duration of the disease and with the therapeutic strategy used to treat it.
机译:改善急慢性肝功能不全患者的生存率和生活质量仍然是一个挑战。基于细胞的治疗性肝细胞移植具有巨大的潜力,可以在供体器官变得可用之前用作临时支持和“桥梁”,甚至可以用作替代受损肝的疗法。在这篇综述中,我们描述了人体组织工程的潜在应用,比较了有或没有组织工程的移植肝细胞的治疗效果,并强调了干细胞移植在肝功能异常中令人兴奋的进展。肝细胞可以以纯细胞的形式移植,也可以以设备(经过或未经过生长因子预处理),新鲜分离或保存的细胞或成年成熟或干细胞工程化的细胞形式移植。不同形式的基于细胞的治疗的功效可能与疾病的严重程度和持续时间以及用于治疗该疾病的治疗策略有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号